Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Chimeric Therapeutics's cash receipts from operating activities for the
six
months ended in Dec. 2025 was $2.99 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
Chimeric Therapeutics's cash payments for the
six
months ended in Dec. 2025 was $-5.53 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
Chimeric Therapeutics's cash payments for the
six
months ended in Dec. 2025 was $0.00 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
Chimeric Therapeutics's cash payments for the
six
months ended in Dec. 2025 was $0.00 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
Chimeric Therapeutics's cash payments for the
six
months ended in Dec. 2025 was $-0.03 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
Chimeric Therapeutics's cash payments for the
six
months ended in Dec. 2025 was $0.02 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
Chimeric Therapeutics's cash payments for the
six
months ended in Dec. 2025 was $0.00 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
Chimeric Therapeutics's cash flow from others for the
six
months ended in Dec. 2025 was $-0.00 Mil.
Chimeric Therapeutics Cash Flow from Operations Related Terms
Chimeric Therapeutics Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for Chimeric Therapeutics's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chimeric Therapeutics Cash Flow from Operations Chart
Chimeric Therapeutics Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Chimeric Therapeutics's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-5.56 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of $-5.56 Mil mean?
Chimeric Therapeutics (CHMMF) has a Cash Flow from Operations of $-5.56 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Chimeric Therapeutics and its competitors.
Is Chimeric Therapeutics' Cash Flow from Operations too high?
Chimeric Therapeutics' current Cash Flow from Operations is $-5.56 Mil. Overall, Chimeric Therapeutics has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Chimeric Therapeutics' Cash Flow from Operations compare to VRTX and REGN?
Chimeric Therapeutics' Cash Flow from Operations of $-5.56 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Chimeric Therapeutics and its competitors. Chimeric Therapeutics's current Cash Flow from Operations is $-5.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chimeric Therapeutics stock overvalued right now?
Chimeric Therapeutics (CHMMF) has a current Cash Flow from Operations of $-5.56 Mil. The current Cash Flow from Operations is $-5.56 Mil. Chimeric Therapeutics' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Chimeric Therapeutics (CHMMF), the current Cash Flow from Operations is $-5.56 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chimeric Therapeutics Ltd is an Australian clinical-stage cell therapy company focused on developing and commercialising a range of cell therapies in oncology. The group's products under development include T Cell Derived Autologous Therapies and Natural Killer (NK) Cell Derived Allogenic Therapies. T Cell Derived Autologous therapy works by engineering the T cells with the exact coordinates to attack and kill cancer. NK Cell Derived Allogenic Therapies from healthy donors can be manufactured on a large scale and, once administered, kill cancer. Its pipeline products include CDH17, CLTX, and CORE NK. The group has one reportable segment, being the research, development, and commercialisation of health technologies.
13GF Score
Get the complete analysis for CHMMF
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHMMF has been successfully added to your 
